|
| Press Releases |
|
 |
|
| Monday, March 18, 2024 |
|
|
亿胜生物公布2023年度业绩，收入增长29.5%，利润增长22.1% |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」；股份代码：1061.HK）今日公布截至2023年12月31日止的年度财务业绩。 more info >> |
|
|
億勝生物公布2023年度業績，收入增長29.5%，利潤增長22.1% |
| 億勝生物科技有限公司（「億勝生物」或「集團」；股份代碼：1061.HK）今日公布截至2023年12月31日止的年度財務業績。 more info >> |
|
|
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1% |
| Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2023. more info >> |
|
| Wednesday, August 16, 2023 |
|
|
亿胜生物公布2023年中期业绩 收入同比增长37.1% 净利润同比增长22.0% |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」；股份代码：1061.HK）今日公布截至2023年6月30日止（「回顾期内」）的中期财务业绩。 more info >> |
|
|
億勝生物公佈2023年中期業績 收入同比增長37.1% 淨利潤同比增長22.0% |
| 億勝生物科技有限公司（「億勝生物」或「集團」；股份代碼：1061.HK）今日公佈截至2023年6月30日止（「回顧期內」）的中期財務業績。 more info >> |
|
|
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22% |
Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").
more info >> |
|
| Wednesday, July 26, 2023 |
|
|
亿胜生物宣布贝伐珠单抗眼科适应症I/II期临床研究成功完成 |
| 亿胜生物科技有限公司（「亿胜生物」或「集团」，股票代码：1061.HK）今日宣布，集团与上海复宏汉霖生物技术股份有限公司（「复宏汉霖」，股票代码：2696.HK）合作开发的重组抗血管内皮生长因子(Vascular endothelial growth factor, VEGF) more info >> |
|
|
億勝生物宣布貝伐珠單抗眼科適應症I/II期臨床研究成功完成 |
| 億勝生物科技有限公司（「億勝生物」或「集團」，股票代碼：1061.HK）今日宣布，集團與上海復宏漢霖生物技術股份有限公司（「復宏漢霖」，股票代碼：2696.HK）合作開發的重組抗血管內皮生長因子(Vascular endothelial growth factor, VEGF) more info >> |
|
|
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc. more info >> |
|
| Friday, April 14, 2023 |
|
|
亿胜生物与Osteopore签订口腔颌面产品在新加坡的独家代理协议 |
| 亿胜生物科技有限公司（“亿胜生物”或“集团”，股票代码：1061.HK）欣然宣布，集团全资附属子公司Majeton Pte. Ltd. ("Majeton")与Osteopore Limited ("Osteopore")达成合作，就Osteopore的牙科和口腔颌面产品("产品")签订独家代理协议。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
SAP商業AI持續釋放數據價值 驅動企業韌性增長
Jun 13, 2025 13:10 HKT/SGT
|
|
|
Ria Money Transfer's New Approval Enables Digital Salary Payments for Malaysia's Migrant Workforce
Jun 13, 2025 13:00: JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 12:46: JST
|
|
|
Ria Money Transfer's New Approval Enables Digital Salary Payments for Malaysia's Migrant Workforce
Jun 13, 2025 12:00 HKT/SGT
|
|
|
TRENDE Announces Strategic Capital and Business Alliance with Tokyu Land
Jun 13, 2025 13:00 JST
|
|
|
ARE Expands India Leadership, Strengthens Regional Role in Climate, Energy, and Food System Transition
Jun 13, 2025 11:46 HKT/SGT
|
|
|
JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million
Jun 12, 2025 21:07 HKT/SGT
|
|
|
健倍苗苗二零二五財年全年業績表現亮眼 純利飆升51.2%至1.97億港元
Jun 12, 2025 20:58 HKT/SGT
|
|
|
健倍苗苗二零二五财年全年业绩表现亮眼 纯利飙升51.2%至1.97亿港元
Jun 12, 2025 20:48 HKT/SGT
|
|
|
品質基石的守護者：檢測檢驗行業賦能高質量發展
Jun 12, 2025 18:28 HKT/SGT
|
|
|
质量基石的守护者：检测检验行业赋能高质量发展
Jun 12, 2025 18:19 HKT/SGT
|
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 17:38: JST
|
|
|
NEFECON(R) and EVER001 Drive Synergistic Progress as Everest Medicines Advances
Jun 12, 2025 16:38 HKT/SGT
|
|
|
耐賦康(R)與EVER001協同發力 雲頂新耀推動腎病治療進入精準管理新階段
Jun 12, 2025 16:31 HKT/SGT
|
|
|
耐赋康(R)与EVER001协同发力 云顶新耀推动肾病治疗进入精准管理新阶段
Jun 12, 2025 16:26 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
